NCT04988295 · ADVERSE EVENTS

Adverse events

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure · Source last updated 2026-08-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: From Cycle 1 Day 1 up to 1 year 7 months
Other-event reporting threshold: 5%

SAEs \& Other AEs:safety set-randomized participants who had at least 1 dose of study drug. All-cause mortality:FAS-all randomized participants, classified per assigned drug regardless of actual drug received. As per statistical analysis, Arm A AE planned to be collected and analyzed as single arm regardless of regimen LACP/ACP-L received. Since extension cohort is ongoing and its data collection and analysis was not planned for primary analysis, AE data will be reported after study completion.

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) LACP dosing (study start until 6 November 2022): Participants received Lazertinib 240 milligrams (mg) orally on Day 1 of each subsequent cycle, starting with Cycle 3, along with Amivantamab 1400 mg (1750 mg if body weight greater than or equal to \[\>=80\] kilograms \[kg\]) on Cycle 1 Days 1, 2, 8, and 15, and Cycle 2 Day 1 and 1750 mg (2100 mg if body weight \>=80 kg). Participant also received Pemetrexed 500 mg per square meter (mg/m\^2) on Day 1 21-day cycle, in combination with carboplatin 750 mg as IV infusion starting on Cycle 1 Day 1 for 4 cycles. From cycle 5 onwards, participants received Amivantamab, Pemetrexed and Lazertinib IV infusions at same dose, as maintenance until disease progression. ACP-L dosing (from 7 November 2022 until study completion): Participants received Amivantamab 1400 mg (1750 mg if body weight \>=80\] kg) on Cycle 1 Days 1,2, 8, and 15, and Cycle 2 Day 1 and 1750 mg (2100 mg if body weight \>=80 kg). Participant also received Pemetrexed 500 mg/m\^2 on Day 1 of each 21-day cycle, in combination with carboplatin 750 mg as IV infusion starting on Cycle 1 Day 1 for 4 cycles. Lazertinib 240 mg in ACP-L started on Cycle 5 Day 1 or sooner if carboplatin is discontinued before cycle 4. From cycle 5 onwards, participants received Amivantamab, Pemetrexed and Lazertinib IV infusions at same dose, as maintenance until disease progression. Each cycle consists of 21 days.	137 / 263	261 / 263	69 / 263
Main Study: Arm B: Carboplatin + Pemetrexed (CP) Participants received Pemetrexed 500 mg/m\^2 IV infusion and carboplatin 750 mg IV infusion from Day 1 of Cycle 1 to 4. From cycle 5 onwards, participants received Pemetrexed 500 mg/m\^2 IV infusion, as maintenance until disease progression. Each cycle consists of 21 days.	49 / 243	222 / 243	65 / 263
Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) Participants received Amivantamab 1400 mg (1750 mg if body weight \>=80 kg) on Cycle 1 Days 1,2, 8, and 15, and Cycle 2 Day 1 and 1750 mg (2100 mg if body weight \>=80 kg) on Day 1 of each cycle, starting with Cycle 3. Participants also received Pemetrexed 500 mg/m\^2 on Day 1 of each 21-day cycle, in combination with carboplatin 750 mg as IV infusion starting on Cycle 1 Day 1 for 4 cycles. From cycle 5 onwards, participants received Amivantamab and Pemetrexed IV infusions at same dose, as maintenance until disease progression. Each cycle consists of 21 days.	42 / 130	129 / 130	27 / 131

Group identifiers: EG000: Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) · EG001: Main Study: Arm B: Carboplatin + Pemetrexed (CP) · EG002: Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP)

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Infections and infestations
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
6
num At Risk
263
group Id
EG001
num Affected
1
num At Risk
243
group Id
EG002
num Affected
3
num At Risk
130
term
Sepsis
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Infections and infestations
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
6
num At Risk
263
group Id
EG001
num Affected
0
num At Risk
243
group Id
EG002
num Affected
2
num At Risk
130
term
Covid-19
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Infections and infestations
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
1
num At Risk
263
group Id
EG001
num Affected
0
num At Risk
243
group Id
EG002
num Affected
2
num At Risk
130
term
Skin Infection
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Infections and infestations
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
2
num At Risk
263
group Id
EG001
num Affected
0
num At Risk
243
group Id
EG002
num Affected
1
num At Risk
130
term
Gastroenteritis
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Infections and infestations
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
0
num At Risk
263
group Id
EG001
num Affected
0
num At Risk
243
group Id
EG002
num Affected
1
num At Risk
130
term
Gastrointestinal Infection
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Infections and infestations
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
0
num At Risk
263
group Id
EG001
num Affected
0
num At Risk
243
group Id
EG002
num Affected
1
num At Risk
130
term
Herpes Virus Infection
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Infections and infestations
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
0
num At Risk
263
group Id
EG001
num Affected
0
num At Risk
243
group Id
EG002
num Affected
1
num At Risk
130
term
Infectious Pleural Effusion
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Infections and infestations
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
2
num At Risk
263
group Id
EG001
num Affected
0
num At Risk
243
group Id
EG002
num Affected
1
num At Risk
130
term
Neutropenic Sepsis
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Infections and infestations
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
0
num At Risk
263
group Id
EG001
num Affected
0
num At Risk
243
group Id
EG002
num Affected
1
num At Risk
130
term
Pneumonia Viral
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Infections and infestations
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
0
num At Risk
263
group Id
EG001
num Affected
0
num At Risk
243
group Id
EG002
num Affected
1
num At Risk
130
term
Soft Tissue Infection
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Infections and infestations
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
1
num At Risk
263
group Id
EG001
num Affected
1
num At Risk
243
group Id
EG002
num Affected
0
num At Risk
130
term
Bacteraemia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Infections and infestations
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
1
num At Risk
263
group Id
EG001
num Affected
0
num At Risk
243
group Id
EG002
num Affected
0
num At Risk
130
term
Bacterial Infection

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
130
num At Risk
263
group Id
EG001
num Affected
90
num At Risk
243
group Id
EG002
num Affected
58
num At Risk
130
term
Nausea
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
96
num At Risk
263
group Id
EG001
num Affected
72
num At Risk
243
group Id
EG002
num Affected
50
num At Risk
130
term
Constipation
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
120
num At Risk
263
group Id
EG001
num Affected
21
num At Risk
243
group Id
EG002
num Affected
41
num At Risk
130
term
Stomatitis
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
75
num At Risk
263
group Id
EG001
num Affected
42
num At Risk
243
group Id
EG002
num Affected
31
num At Risk
130
term
Vomiting
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
66
num At Risk
263
group Id
EG001
num Affected
16
num At Risk
243
group Id
EG002
num Affected
17
num At Risk
130
term
Diarrhoea
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
13
num At Risk
263
group Id
EG001
num Affected
6
num At Risk
243
group Id
EG002
num Affected
7
num At Risk
130
term
Abdominal Pain
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
6
num At Risk
263
group Id
EG001
num Affected
1
num At Risk
243
group Id
EG002
num Affected
7
num At Risk
130
term
Dry Mouth
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
22
num At Risk
263
group Id
EG001
num Affected
1
num At Risk
243
group Id
EG002
num Affected
7
num At Risk
130
term
Haemorrhoids
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
173
num At Risk
263
group Id
EG001
num Affected
98
num At Risk
243
group Id
EG002
num Affected
73
num At Risk
130
term
Neutropenia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
156
num At Risk
263
group Id
EG001
num Affected
69
num At Risk
243
group Id
EG002
num Affected
57
num At Risk
130
term
Thrombocytopenia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
141
num At Risk
263
group Id
EG001
num Affected
96
num At Risk
243
group Id
EG002
num Affected
50
num At Risk
130
term
Anaemia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
106
num At Risk
263
group Id
EG001
num Affected
67
num At Risk
243
group Id
EG002
num Affected
37
num At Risk
130
term
Leukopenia

Complete source fields

description

event Groups

deaths Num Affected
69
deaths Num At Risk
263
description
LACP dosing (study start until 6 November 2022): Participants received Lazertinib 240 milligrams (mg) orally on Day 1 of each subsequent cycle, starting with Cycle 3, along with Amivantamab 1400 mg (1750 mg if body weight greater than or equal to \[\>=80\] kilograms \[kg\]) on Cycle 1 Days 1, 2, 8, and 15, and Cycle 2 Day 1 and 1750 mg (2100 mg if body weight \>=80 kg). Participant also received Pemetrexed 500 mg per square meter (mg/m\^2) on Day 1 21-day cycle, in combination with carboplatin 750 mg as IV infusion starting on Cycle 1 Day 1 for 4 cycles. From cycle 5 onwards, participants received Amivantamab, Pemetrexed and Lazertinib IV infusions at same dose, as maintenance until disease progression. ACP-L dosing (from 7 November 2022 until study completion): Participants received Amivantamab 1400 mg (1750 mg if body weight \>=80\] kg) on Cycle 1 Days 1,2, 8, and 15, and Cycle 2 Day 1 and 1750 mg (2100 mg if body weight \>=80 kg). Participant also received Pemetrexed 500 mg/m\^2 on Day 1 of each 21-day cycle, in combination with carboplatin 750 mg as IV infusion starting on Cycle 1 Day 1 for 4 cycles. Lazertinib 240 mg in ACP-L started on Cycle 5 Day 1 or sooner if carboplatin is discontinued before cycle 4. From cycle 5 onwards, participants received Amivantamab, Pemetrexed and Lazertinib IV infusions at same dose, as maintenance until disease progression. Each cycle consists of 21 days.
id
EG000
other Num Affected
261
other Num At Risk
263
serious Num Affected
137
serious Num At Risk
263
title
Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L)
deaths Num Affected
65
deaths Num At Risk
263
description
Participants received Pemetrexed 500 mg/m\^2 IV infusion and carboplatin 750 mg IV infusion from Day 1 of Cycle 1 to 4. From cycle 5 onwards, participants received Pemetrexed 500 mg/m\^2 IV infusion, as maintenance until disease progression. Each cycle consists of 21 days.
id
EG001
other Num Affected
222
other Num At Risk
243
serious Num Affected
49
serious Num At Risk
243
title
Main Study: Arm B: Carboplatin + Pemetrexed (CP)
deaths Num Affected
27
deaths Num At Risk
131
description
Participants received Amivantamab 1400 mg (1750 mg if body weight \>=80 kg) on Cycle 1 Days 1,2, 8, and 15, and Cycle 2 Day 1 and 1750 mg (2100 mg if body weight \>=80 kg) on Day 1 of each cycle, starting with Cycle 3. Participants also received Pemetrexed 500 mg/m\^2 on Day 1 of each 21-day cycle, in combination with carboplatin 750 mg as IV infusion starting on Cycle 1 Day 1 for 4 cycles. From cycle 5 onwards, participants received Amivantamab and Pemetrexed IV infusions at same dose, as maintenance until disease progression. Each cycle consists of 21 days.
id
EG002
other Num Affected
129
other Num At Risk
130
serious Num Affected
42
serious Num At Risk
130
title
Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP)

frequency Threshold

other Events

assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
130
num At Risk
263
group Id
EG001
num Affected
90
num At Risk
243
group Id
EG002
num Affected
58
num At Risk
130
term
Nausea
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
96
num At Risk
263
group Id
EG001
num Affected
72
num At Risk
243
group Id
EG002
num Affected
50
num At Risk
130
term
Constipation
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
120
num At Risk
263
group Id
EG001
num Affected
21
num At Risk
243
group Id
EG002
num Affected
41
num At Risk
130
term
Stomatitis
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
75
num At Risk
263
group Id
EG001
num Affected
42
num At Risk
243
group Id
EG002
num Affected
31
num At Risk
130
term
Vomiting
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
66
num At Risk
263
group Id
EG001
num Affected
16
num At Risk
243
group Id
EG002
num Affected
17
num At Risk
130
term
Diarrhoea
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
13
num At Risk
263
group Id
EG001
num Affected
6
num At Risk
243
group Id
EG002
num Affected
7
num At Risk
130
term
Abdominal Pain
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
6
num At Risk
263
group Id
EG001
num Affected
1
num At Risk
243
group Id
EG002
num Affected
7
num At Risk
130
term
Dry Mouth
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
22
num At Risk
263
group Id
EG001
num Affected
1
num At Risk
243
group Id
EG002
num Affected
7
num At Risk
130
term
Haemorrhoids
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
173
num At Risk
263
group Id
EG001
num Affected
98
num At Risk
243
group Id
EG002
num Affected
73
num At Risk
130
term
Neutropenia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
156
num At Risk
263
group Id
EG001
num Affected
69
num At Risk
243
group Id
EG002
num Affected
57
num At Risk
130
term
Thrombocytopenia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
141
num At Risk
263
group Id
EG001
num Affected
96
num At Risk
243
group Id
EG002
num Affected
50
num At Risk
130
term
Anaemia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
106
num At Risk
263
group Id
EG001
num Affected
67
num At Risk
243
group Id
EG002
num Affected
37
num At Risk
130
term
Leukopenia

serious Events

assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Infections and infestations
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
6
num At Risk
263
group Id
EG001
num Affected
1
num At Risk
243
group Id
EG002
num Affected
3
num At Risk
130
term
Sepsis
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Infections and infestations
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
6
num At Risk
263
group Id
EG001
num Affected
0
num At Risk
243
group Id
EG002
num Affected
2
num At Risk
130
term
Covid-19
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Infections and infestations
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
1
num At Risk
263
group Id
EG001
num Affected
0
num At Risk
243
group Id
EG002
num Affected
2
num At Risk
130
term
Skin Infection
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Infections and infestations
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
2
num At Risk
263
group Id
EG001
num Affected
0
num At Risk
243
group Id
EG002
num Affected
1
num At Risk
130
term
Gastroenteritis
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Infections and infestations
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
0
num At Risk
263
group Id
EG001
num Affected
0
num At Risk
243
group Id
EG002
num Affected
1
num At Risk
130
term
Gastrointestinal Infection
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Infections and infestations
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
0
num At Risk
263
group Id
EG001
num Affected
0
num At Risk
243
group Id
EG002
num Affected
1
num At Risk
130
term
Herpes Virus Infection
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Infections and infestations
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
0
num At Risk
263
group Id
EG001
num Affected
0
num At Risk
243
group Id
EG002
num Affected
1
num At Risk
130
term
Infectious Pleural Effusion
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Infections and infestations
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
2
num At Risk
263
group Id
EG001
num Affected
0
num At Risk
243
group Id
EG002
num Affected
1
num At Risk
130
term
Neutropenic Sepsis
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Infections and infestations
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
0
num At Risk
263
group Id
EG001
num Affected
0
num At Risk
243
group Id
EG002
num Affected
1
num At Risk
130
term
Pneumonia Viral
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Infections and infestations
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
0
num At Risk
263
group Id
EG001
num Affected
0
num At Risk
243
group Id
EG002
num Affected
1
num At Risk
130
term
Soft Tissue Infection
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Infections and infestations
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
1
num At Risk
263
group Id
EG001
num Affected
1
num At Risk
243
group Id
EG002
num Affected
0
num At Risk
130
term
Bacteraemia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Infections and infestations
source Vocabulary
MedDRA Version 25.0
stats
group Id
EG000
num Affected
1
num At Risk
263
group Id
EG001
num Affected
0
num At Risk
243
group Id
EG002
num Affected
0
num At Risk
130
term
Bacterial Infection

time Frame

From Cycle 1 Day 1 up to 1 year 7 months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice